SCHEMBL1936906

SCHEMBL1936906

Cc1ccc(C(=O)NC2(c3ccc(F)cc3)CC2)cc1N(C)C(=O)c1cnn2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
HTT P42858 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.41
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2C8 P10632 3/20 0.39
EPHB3 P54753 1/20 0.38
IDO1 P14902 6/20 0.38
TP53 P04637 1/20 0.38
MAST3 O60307 1/20 0.37
MAPK8 P45983 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1934827 0.77 CYP2C8 (0.48) CYP3A4CYP2C8EPHB3MAPK8
SCHEMBL1935003 0.76 EPHB3 (0.40) NPC1RAB9AHTTALDH1A1SMN1; SMN2
SCHEMBL1937087 0.74 CYP2C8 (0.44) CYP3A4CYP2C8IDO1
SCHEMBL1936907 0.72 CYP2C8 (0.54) CYP3A4CYP2C8IDO1MAST3MAPK8
SCHEMBL10834334 0.64 NPC1 (0.52) NPC1RAB9AHTTALDH1A1SMN1; SMN2
SCHEMBL17867589 0.63 NPC1 (0.51) NPC1RAB9AHTTALDH1A1SMN1; SMN2
SCHEMBL32683984 0.62 AKT1 (0.43) NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL9911902 0.62 CYP2C8 (0.62) CYP3A4CYP2C8IDO1
SCHEMBL1935412 0.62 CYP2C8 (0.57) CYP3A4CYP2C8IDO1MAST3MAPK8
SCHEMBL13184794 0.62 MAPK14 (0.59) NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331502-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2011-06-15 EP disclosed
WO-2010030538-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 WO disclosed